Hajar AlQahtani

Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial

Mohammad Bosaeed, Ahmad M. Alharbi, Ebrahim Mahmoud et al. · Clinical Microbiology and Infection · 2022 · 103 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

<p>Antibacterial Activity of Chitosan Nanoparticles Against Pathogenic N. gonorrhoea</p>

Fulwah Yahya Alqahtani, Fadilah Sfouq Aleanizy, Hiba Alhabib et al. · International Journal of Nanomedicine · 2020 · 83 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Evaluating the effect of antibiotics sub-inhibitory dose on Pseudomonas aeruginosaquorum sensing dependent virulence and its phenotypes

Fadilah Sfouq Aleanizy, Fulwah Yahya Alqahtani, Esra Kamal Eltayb et al. · Saudi Journal of Biological Sciences · 2020 · 24 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial

Mohammad Bosaeed, Ebrahim Mahmoud, Ahmad M. Alharbi et al. · Infectious Diseases and Therapy · 2021 · 22 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Clinical characteristics and risk factors of patients with severe COVID-19 in Riyadh, Saudi Arabia: A retrospective study

Fadilah Sfouq Aleanizy, Fulwah Yahya Alqahtani, Marzouqah S. Alanazi et al. · Journal of Infection and Public Health · 2021 · 17 citations · Full text

Veterinary Medicine, Infectious Diseases, Emerging Infectious Diseases +15